title: Thiazolidinedione (pioglitazone) blocks P. gingivalis- and F. nucleatum, but not E. coli, lipopolysaccharide (LPS)-induced interleukin-6 (IL-6) production in adipocytes.
abstract: An elevated level of C-reactive protein (CRP) predicts the future development of coronary heart disease. Periodontitis appears to up-regulate CRP. CRP is produced by hepatocytes in response to interleukin-6 (IL-6). A major source of IL-6 in obese subjects is adipocytes. We hypothesized that lipopolysaccharide (LPS) from periodontal pathogens stimulated adipocytes to produce IL-6, and that the production was suppressed by the drugs targeted against insulin resistance, thiazolidinedione (pioglitazone), since this agent potentially showed an anti-inflammatory effect. Mouse 3T3-L1 adipocytes were stimulated with E. coli, P. gingivalis, and F. nucleatum LPS. The IL-6 concentration in culture supernatants was measured. All LPS stimulated adipocytes to produce IL-6. Although pioglitazone changed adipocyte appearance from large to small, and completely suppressed P. gingivalis and F. nucleatum LPS-induced IL-6 production, E. coli LPS-induced IL-6 production was not efficiently blocked. Thus, pioglitazone completely blocked periodontal-bacteria-derived LPS-induced IL-6 production in adipocytes, a major inducer of CRP.
authors.affiliation: Department of Patho-physiology/Periodontal Science, Okayama University Graduate School of Medicine and Dentistry, 2-5-1 Shikata-cho, Okayama 700-8525, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Yamaguchi
authors.forename: F
authors.initials: F
authors.lastname: Nishimura
authors.forename: H
authors.initials: H
authors.lastname: Naruishi
authors.forename: Y
authors.initials: Y
authors.lastname: Soga
authors.forename: S
authors.initials: S
authors.lastname: Kokeguchi
authors.forename: S
authors.initials: S
authors.lastname: Takashiba
mesh_terms: D016475:3T3 Cells; D017667:Adipocytes / Q000187:drug effects* / Q000276:immunology; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000494:pharmacology*; D002097:C-Reactive Protein / Q000037:antagonists & inhibitors; D048429:Cell Size / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004926:Escherichia coli; D016967:Fusobacterium nucleatum; D007333:Insulin Resistance; D008070:Lipopolysaccharides / Q000494:pharmacology*; D051379:Mice; D000077205:Pioglitazone; D016966:Porphyromonas gingivalis; D045162:Thiazolidinediones / Q000008:administration & dosage / Q000494:pharmacology*; D000093242:Interleukin-6 Inhibitors
chemical_list: D000893:Anti-Inflammatory Agents; D002097:C-Reactive Protein; D008070:Lipopolysaccharides; D000077205:Pioglitazone; D045162:Thiazolidinediones; D000093242:Interleukin-6 Inhibitors